Heterotopic ossification after hip arthroplasty:A randomized double-blind multicenter study of tenoxicam in 147 hips
| Autor: | Michael Crawford, Jens Sletgård, Antero Hänninen, Peter Gebuhr, Kjell Keisu, Jesper Dalsgård, Michael Soelberg |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
medicine.medical_specialty
medicine.medical_treatment Placebo Prosthesis Piroxicam Postoperative Complications Double-Blind Method Tenoxicam Humans Medicine Orthopedics and Sports Medicine Chemotherapy business.industry Ossification Ossification Heterotopic Anti-Inflammatory Agents Non-Steroidal medicine.disease Surgery Treatment Outcome Anesthesia Morphine Heterotopic ossification Hip Prosthesis medicine.symptom business Complication medicine.drug |
| Zdroj: | Acta Orthopaedica Scandinavica. 67:29-32 |
| ISSN: | 0001-6470 |
| DOI: | 10.3109/17453679608995604 |
| Popis: | 147 patients due to have a cemented total hip arthroplasty were randomized to 4 groups. They received either tenoxicam 20 mg or 40 mg, or placebo, for 5 days or morphine on the day of operation and placebo for 4 days. During the first 5 days 14 patients were excluded. The patients were followed for 1 year, during which another 10 patients were excluded. At follow-up, significantly fewer patients had heterotopic ossifications in the tenoxicam groups than in the placebo and morphine groups. There was no significant difference between the 2 tenoxicam-treated groups, and we therefore conclude that tenoxicam 20 mg for 5 days postoperatively can reduce heterotopic ossification after cemented total hip arthroplasty. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|